TTLTicker Tales
NSE: TORNTPHARMHealthcare

Torrent Pharmaceuticals

Torrent Pharma is an Ahmedabad-based pharma company selling branded generics (cardiac, CNS, diabetes, GI) in India, Brazil, Germany and the US, and after absorbing JB Chemicals & Pharmaceuticals in 2026 it also runs a large OTC/consumer-health and CDMO business.

₹4,595.00▲+27.8%1 yearClosing price, 2 Nov 2026
  • P/E ~78-80x
  • Debt/Equity 1.8x (record high)
  • Promoter 60.8%, zero pledge
  • 1Y return +28% vs Nifty -9%
  • Q2 PAT fell 9.6% despite 52% revenue jump

Updated on 3 Nov 2026 · Data as of 2 Nov 2026

Get this report as a PDF free, straight to your inbox.

Snapshot

Share price
₹4,595.00
2 Nov 2026
52-week range
₹3,522.20 – ₹5,122.80
All-time peak
₹5,122.80
31 Jul 2026 · −10.3% from peak
Dividend yield
0.83%
Price history since
2002
About 24 years of prices
52-week low ₹3,522.20high ₹5,122.80

What's happening

Q2 FY27 results (23 Oct 2026): consolidated revenue rose 51.7% YoY to ₹4,979 crore, driven by the JB Chemicals & Pharmaceuticals merger (effective 8 July 2026) plus 18% organic growth in the base business. Operating EBITDA jumped 54% to ₹1,666 crore (margin ~33.5%), but net profit fell 9.6% YoY to ₹534 crore because finance costs jumped to ₹300 crore (from ₹48 crore) and amortisation to ₹609 crore (from ₹204 crore) on the back of acquisition accounting. Executive Director Amal Kelshikar resigned effective 16 October 2026.

In plain terms

The 52% revenue jump is not organic magic — it mostly reflects JB Chemicals' sales now sitting inside Torrent's books after the July 2026 merger, so this quarter and last year's quarter are not strictly comparable. The operating business did get genuinely bigger and more profitable at the EBITDA line, which is the cleaner number to watch. But net profit actually fell, because the ₹25,689-crore JB Pharma deal was funded partly with debt, and the interest plus amortisation of acquired intangibles are now a real, recurring drag on the bottom line — not a one-off.

Quarters

Trend: Q3 FY26 PAT ₹635cr (+26% YoY) → Q4 FY26 PAT ₹364cr (-27%, hit by ₹66cr exceptional items and higher intangible amortisation) → Q1 FY27 PAT ₹566cr (revenue +55%, but a temporary semaglutide supply shortfall from a manufacturing partner cost sales in July-August) → Q2 FY27 PAT ₹534cr (-9.6%, revenue +51.7%). Management says JB Pharma cost synergies are tracking ahead of the original ₹90cr target and should now exceed ₹100cr. Revenue and EBITDA comparisons across these quarters are not strictly comparable pre- and post-merger; PAT and EBITDA margin are the more honest gauges.

Performance

Heads-up on splits: Torrent Pharmaceuticals has split its shares or issued bonus shares before (most recently 2-for-1 on 8 Jul 2022, 2-for-1 on 23 Jul 2013 and 2-for-1 on 20 Feb 2006). A sudden price drop around a split date is usually just the price adjusting for the extra shares, not a crash.

Share price

+27.8% over 1 year

Returns by period

PeriodTorrent PharmaceuticalsNifty 50Sun Pharmaceutical Industries
3 months−9.0%−5.4%−9.8%
1 year+27.8%−9.0%+4.7%
3 years+141.3%+21.9%+59.4%
5 years+243.7%+31.0%+128.1%

₹100 invested on 2 Nov 2021 became…

  • Torrent Pharmaceuticals₹344
  • Nifty 50₹131
  • Sun Pharmaceutical Industries₹228

Stock has sharply beaten both the Nifty and peer Sun Pharma: +27.8% over 1 year (Nifty -9.0%, peer +4.7%), +141.3% over 3 years (Nifty +21.9%, peer +59.4%), +243.7% over 5 years (Nifty +31.0%, peer +128.1%). It is down 10.3% from its 31 July 2026 peak of ₹5,122.8, which lines up with the market digesting the JB Pharma merger completion and the subsequent profit dip — this looks like a normal post-event correction, not a crash. The stock has had three 2:1 stock splits (2006, 2013, 2022) with no demerger involved, so the long-run price series already reflects these and understates nothing.

Dividend

Paid in the last 12 months

₹38.00 per share

Dividend yield

0.83%

Dividend yield is the last 12 months of dividends divided by today's share price. A 0.8% yield means every ₹100 of Torrent Pharmaceuticals shares paid about ₹0.8 in dividends over the past year. Past payouts can change.

Recent dividends

DatePer share
29 May 2026₹9.00
18 Feb 2026₹29.00
20 Jun 2025₹6.00
31 Jan 2025₹26.00
21 Jun 2024₹6.00
12 Feb 2024₹22.00
23 Jun 2023₹8.00
3 Feb 2023₹14.00

Valuation

P/E is roughly 78-81x (cross-checked across two independent sources using current price and TTM EPS of ~₹59) versus a peer median near 31x; P/B is roughly 20x versus a peer median near 5x. Why it looks expensive: trailing EPS is currently depressed by merger-related finance costs and intangible amortisation, which mechanically inflates the P/E even though the underlying EBITDA is growing fast. Whether it is actually expensive is a separate question — the multiple is also high relative to Torrent's own history, so the market is pricing in flawless JB Pharma integration and synergy delivery, not just a temporary accounting dip.

Growth

Growth is currently both volume- and merger-led: India formulations grew 18-19% against industry growth of ~12%, and the OTC arm (Curatio) grew 34%, while Brazil and the US also grew; Germany was a weak spot. EBITDA margin expanded to ~33.5-33.8%, so this isn't purely a low-margin volume grab. However, the bulk of the reported revenue increase (51-55% YoY) comes from consolidating JB Chemicals, so headline growth numbers should not be read as organic.

Health

Reported ROE is ~26.8% and ROCE ~19.3%, both still healthy, but debt-to-equity has risen to roughly 1.8x — the highest in the company's history — after funding the ~₹25,689 crore JB Pharma acquisition with a mix of cash (₹11,917cr) and an open offer. The operating business is cash-generative (EBITDA margin above 33%), so the near-term concern is financial risk (leverage and deleveraging pace), not business risk.

Ownership

Promoter entity Torrent Investments Limited holds 60.78% as of September 2026 with zero shares pledged — a clean, high promoter stake. Institutional holding is split between FIIs (~8.4%) and DIIs (~13.46%), with public shareholding around 6.95%. No marquee individual investor shows up in the available shareholding data.

The View

The one thing to watch

Whether consolidated PAT re-accelerates over the next 2-3 quarters as JB Pharma synergies (now targeted above ₹100 crore) land and finance/amortisation costs stop outgrowing EBITDA — that is what will show whether the current profit dip is a temporary accounting artifact of the merger or a more lasting drag.

Strengths

  • +Operating EBITDA grew 54% YoY to ₹1,666 crore in Q2 FY27 with margin near 33.5%
  • +India formulations business grew 18-19% YoY, outpacing industry growth of ~12%
  • +Promoter holds 60.78% with zero pledge
  • +Bileshwarpura and Dahej plants both cleared 2026 USFDA inspections with zero observations, important for continued US exports

Watchpoints

  • !Debt-to-equity at a record ~1.8x after the debt-funded JB Pharma deal; pace of deleveraging is unproven
  • !Consolidated PAT fell 9.6% YoY in Q2 FY27 to ₹534 crore even as revenue and EBITDA grew sharply, due to higher finance costs (₹48cr→₹300cr) and amortisation (₹204cr→₹609cr)
  • !Executive Director Amal Kelshikar resigned effective 16 October 2026
  • !P/E of ~78-81x is well above the peer median of ~31x, leaving little room for integration missteps

How sure are we about the data? · Moderate

Quarterly revenue/PAT figures for Q3 FY26 through Q2 FY27 were cross-checked across Business Standard, Kotak Neo, Equitybulls, Investing.com and scanx.trade and were consistent. One source (Value Research) reported TTM net profit of ₹4,492 crore, which does not reconcile with summing the last four reported quarters (₹635+364+566+534 ≈ ₹2,099 crore) — this figure was treated as unreliable and not used; EPS (~₹59) and the resulting P/E (~78-81x) were corroborated across two independent sources instead. Promoter pledge and shareholding percentages came from a shareholding aggregator rather than a primary BSE/NSE filing, so treat as reasonably but not perfectly reliable. No results date, record date or AGM was found within the next two weeks of 2026-11-03.

Keep it for later

Get the Torrent Pharmaceuticals report as a PDF

The full report, neatly laid out with charts and tables, sent to your inbox. Handy to read offline or share.

Free. We use your email only to send this report and the newsletter.

Share this X LinkedIn WhatsApp

← All Nifty 100 companies

Reports are refreshed every quarter, about three days after each company announces its results.

Ticker Tales is not a SEBI-registered investment adviser or research analyst. This report is for learning only and is not investment advice. Data as of 2 Nov 2026.